Advertisement

Breast Cancer Research and Treatment

, Volume 173, Issue 1, pp 1–9 | Cite as

Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis

  • Y. ShenEmail author
  • T. Fujii
  • N. T. Ueno
  • D. Tripathy
  • N. Fu
  • H. Zhou
  • J. Ning
  • L. Xiao
Review

Abstract

Background

Trastuzumab (H) with chemotherapy benefits patients with HER2+ breast cancer (BC); however, we lack head-to-head pairwise assessment of survival or cardiotoxicity for specific combinations. We sought to identify optimal combinations.

Methods

We searched PubMed, updated October 2017, using keywords “Breast Neoplasms/drug therapy,” “Trastuzumab,” and “Clinical Trial” and searched Cochrane Library. Our search included randomized trials of adjuvant H plus chemotherapy for early-stage HER2+ BC, and excluding trials of neoadjuvant therapy or without data to obtain hazard ratios (HRs) for outcomes. Following PRISMA guidelines, one investigator did initial search; two others independently confirmed and extracted information; and consensus with another investigator resolved disagreements. Before gathering data, we set outcomes of overall survival (OS), event-free survival (EFS), and severe cardiac adverse events (SCAEs). Analyzing 6 trials and 13,621 patients, we made direct and indirect comparisons using network meta-analysis on HR for OS or EFS and on odds ratio (OR) for SCAE; ranked therapy was done based on outcomes using p scores.

Results

Compared with anthracycline-cyclophosphamide with taxane (ACT), ACT with concurrent H (ACT+H) showed best OS (HR 0.63, 95% confidence interval [CI] 0.55, 0.72), followed by taxane and carboplatin (TC) with concurrent H (TC+H) (HR 0.77, 95% CI 0.59, 1) and ACT with sequential H (ACT-H) (HR 0.85, 95% CI 0.68, 1.05). Pairwise comparisons showed statistically significant OS benefit for ACT+H over others; similar results for EFS. TC+H showed statistically significant lower SCAE risk compared to ACT+H (OR 0.13, 95% CI 0.03, 0.61).

Conclusions

Concurrent H with ACT or TC showed most clinical benefit for early-stage HER2+ BC; TC+H had lowest cardiotoxicity.

Keywords

Anthracycline Carboplatin Cardiotoxicity Cyclophosphamide Overall survival Taxane 

Notes

Acknowledgements

LeeAnn Chastain, BA, of the Department of Biostatistics at The University of Texas MD Anderson Cancer Center provided scientific editing services.

Author Contributions

YS and LX have full access to all of the data in the study collected from literature, and take responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: YS, TF, NTU, and LX. Acquisition, analysis, or interpretation of data: YS, LX, TF, NF, JN, HZ, NTU, and DT. Drafting of the manuscript: YS, LX, and TF. Critical revision of the manuscript for important intellectual content: YS, LX, TF, NTU, DT, JN, and NF. Statistical analysis: LX, HZ, JN, and YS. Obtained funding: YS, JN, and NTU. Administrative, technical, or material support: NF, YS, and LX. Study supervision: YS and NTU.

Funding

This study was partially supported by MD Anderson Cancer Center Support Grant from NCI (Grant CA016672), which supports the Biostatistics Share Resource.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

10549_2018_4969_MOESM1_ESM.doc (393 kb)
Supplementary material 1 (DOC 393 KB)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics (2016) CA Cancer J Clin 2016; 66(1):7–30Google Scholar
  2. 2.
    Hynes N, Stern DF (1994) The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198(2–3):165–184Google Scholar
  3. 3.
    Yarden Y, Sliwkowsk MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137Google Scholar
  4. 4.
    Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235(4785):177–182Google Scholar
  5. 5.
    Slamon DJ, Goldophin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712Google Scholar
  6. 6.
    Arboleda MJ, Lyons JF, Kabbinavar FF et al (2003) Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63(1):196–206Google Scholar
  7. 7.
    Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85–95Google Scholar
  8. 8.
    De Luca A, Carotenuto A, Rachiglio A et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214(3):559–567Google Scholar
  9. 9.
    Feigin ME, Muthuswamy SK (2009) ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res 315(4):707–716Google Scholar
  10. 10.
    Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an antiangiogenic cocktail. Nature 416(6878):279–280Google Scholar
  11. 11.
    Marcotte R, Muller WJ (2008) Signal transduction in transgenic mouse models of human breast cancer—implications for human breast cancer. J Mammary Gland Biol Neoplasia 13(3):323–335Google Scholar
  12. 12.
    Pietras RJ, Arboleda J, Reese DM et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10(12):2435–2446Google Scholar
  13. 13.
    She QB, Chandarlapaty S, Ye Q et al (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3(8):e3065Google Scholar
  14. 14.
    Baselga J, Carbonell X, Castañeda-Soto NJ et al (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23(10):162–171Google Scholar
  15. 15.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792Google Scholar
  16. 16.
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (2015) https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 5 Aug 2015
  17. 17.
    De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53Google Scholar
  18. 18.
    Gandhi S, Fletcher GG, Eisen A et al (2015) Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 22(Suppl 1):S82–S94Google Scholar
  19. 19.
    Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811–7819Google Scholar
  20. 20.
    Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752Google Scholar
  21. 21.
    Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792–3799Google Scholar
  22. 22.
    Perez EA, Suman VJ, Davidson NE et al (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29(34):4491–4497Google Scholar
  23. 23.
    Genentech. Herceptin (trastuzumab) development timeline. Genentech product information. https://www.gene.com/media/product-information/herceptin-development-timeline. Accessed 20 Oct 2017
  24. 24.
    Peto R, Davies C, Godwin J et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444Google Scholar
  25. 25.
    Blum JL, Flynn PJ, Yothers G et al (2017) Anthracyclines in early breast cancer: the ABC Trials—USOR 06–090, NSABP B-46-I/USOR 07132, NSABP B-49 (NRG Oncology). J Clin Oncol 35:2647–2655Google Scholar
  26. 26.
    Bafeta A, Trinquart L, Seror R, Ravaud P (2014) Reporting of results from network meta-analyses: methodological systematic review. BMJ 348:g1741Google Scholar
  27. 27.
    Neupane B, Richer D, Bonner AJ et al (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS ONE 9(12):e115065Google Scholar
  28. 28.
    Zhang J, Carlin BP, Neaton JD et al (2014) Network meta-analysis of randomized clinical trials: reporting the proper summaries. Clin Trials 11(2):246–262Google Scholar
  29. 29.
    Tonin FS, Rotta I, Mendes AM, Pontarolo R (2017) Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada) 15(1):943Google Scholar
  30. 30.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):31–34Google Scholar
  31. 31.
    Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27(34):5685–5692Google Scholar
  32. 32.
    Spielmann M, Roché H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134Google Scholar
  33. 33.
    Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in Her2-positive breast cancer. N Engl J Med 365(14):1273–1283Google Scholar
  34. 34.
    Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205Google Scholar
  35. 35.
    Goldstein LJ, O’Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26(25):4092–4099Google Scholar
  36. 36.
    Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313Google Scholar
  37. 37.
    Martín M, Seguí MA, Antón A et al (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363(23):2200–2210Google Scholar
  38. 38.
    Higgins J, Green S. (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. the cochrane collaboration. https://www.cochrane-handbook.org.
  39. 39.
    Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 17(24):2815–2834. Erratum in Stat Med 2004; 23(11): 1817Google Scholar
  40. 40.
    Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16Google Scholar
  41. 41.
    Rücker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3(4):312–324Google Scholar
  42. 42.
    Rücker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58Google Scholar
  43. 43.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560Google Scholar
  44. 44.
    Krahn U, Binder H, König J (2013) A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 13:35Google Scholar
  45. 45.
    Jackson D, White IR, Riley RD (2012) Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31(29):3805–3820Google Scholar
  46. 46.
    Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028Google Scholar
  47. 47.
    Clinical Trials.gov. Trial Identifier: NCT00021255. Cancer International Research Group. https://clinicaltrials.gov/ct2/show/NCT00021255. Accessed 30 Nov 2017
  48. 48.
    Dahabreh IJ, Linardou H, Siannis F et al (2008) Trastuzumab in the adjuvant treatment of early stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6):620–630Google Scholar
  49. 49.
    Viani GA, Afonso SL, Stefano EJ et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153Google Scholar
  50. 50.
    Nagayama A, Hayashida T, Jinno H et al (2014) Comparative effectiveness of neoadjuvant therapy for HER2–positive breast cancer: a network meta-analysis. J Natl Cancer Inst 106(9):pii:dju203Google Scholar
  51. 51.
    Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222–4228Google Scholar
  52. 52.
    Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29(29):3877–3884Google Scholar
  53. 53.
    Gradishar WG, Anderson BO, Blair SL et al (2014) Breast cancer version 3.2014. J Natl Compr Cancer Netw 12(4):542–590Google Scholar
  54. 54.
    Ganz PA, Land SR, Geyer CE et al (2009) NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Res 69(2 Suppl):Abst 76Google Scholar
  55. 55.
    Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119Google Scholar
  56. 56.
    Minckwitz G, Procter MJ et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131Google Scholar
  57. 57.
    Moreno-Aspitia A, Holmes EM et al (2017) Updated results from the phase III ALTTO trial (BIG 2–06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol 35:15_suppl, 502–502Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Section of Translational Breast Cancer, Department of Breast Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations